3-(4-pyridyl)-1,2,4-thiadiazole-5-thiol | 156122-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(4-pyridyl)-1,2,4-thiadiazole-5-thiol
• 英文别名: 3-pyridin-4-yl-2H-1,2,4-thiadiazole-5-thione
• CAS: 156122-19-9
• 化学式: C₇H₅N₃S₂
• 分子量: 195.269
• InChiKey: BETKWXPWNCGYLX-UHFFFAOYSA-N

物化性质

• 沸点：
  328.4±34.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-pyridyl)-1,2,4-thiadiazole-5-thiol 在 吡啶 、 五氯化磷 、 sodium hydride 、 苯甲醚 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

  摘要：

  Crystalline 1 (TAK-599) is a novel N-phosphono prodrug of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin 2a (T-91825) that has high affinity for penicillin-binding protein (PBP) 2' (IC50; 0.90 mug/mL) and shows potent in vitro anti-MRSA activity (MIC against MRSA N133; 1.56 mug/mL), comparable to that of vancomycin (1.56 mug/mL). Although 2a had insufficient water solubility (2.3 mg/mL) for parenteral administration, 1 showed excellent water solubility (> 100 mg/mL, pH 7) as well as good chemical stability in the solid state and solution. In pharmacokinetic studies, when 1 was administered intravenously to rats and monkeys, it was rapidly converted into 2a in the blood. These results show that 1 (TAK-599) is a highly promising parenteral cephalosporin targeted for MRSA infection. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00126-3
• 作为产物：
  描述：

  二硫化碳 、 4-amidinopyridine hydrochloride 在 sodium methylate 、 sulfur 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以50%的产率得到3-(4-pyridyl)-1,2,4-thiadiazole-5-thiol
  参考文献：
  名称：

  TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

  摘要：

  Crystalline 1 (TAK-599) is a novel N-phosphono prodrug of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin 2a (T-91825) that has high affinity for penicillin-binding protein (PBP) 2' (IC50; 0.90 mug/mL) and shows potent in vitro anti-MRSA activity (MIC against MRSA N133; 1.56 mug/mL), comparable to that of vancomycin (1.56 mug/mL). Although 2a had insufficient water solubility (2.3 mg/mL) for parenteral administration, 1 showed excellent water solubility (> 100 mg/mL, pH 7) as well as good chemical stability in the solid state and solution. In pharmacokinetic studies, when 1 was administered intravenously to rats and monkeys, it was rapidly converted into 2a in the blood. These results show that 1 (TAK-599) is a highly promising parenteral cephalosporin targeted for MRSA infection. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00126-3

文献信息

• [EN] NEMATICIDAL DIFLUOROALKENES<br/>[FR] DIFLUOROALCENES NEMATICIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：WO2005026139A1

  公开（公告）日：2005-03-24

  The invention relates to a compound of the formula (I) wherein R represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkylthioalkyl, haloalkyl, alkoxy, alkylthio, represents optionally substituted phenyl or benzyl, or represents optionally substituted heteroaryl containing at least one heteroatom selected from N, O and S, m represents 3, 4, 5, 6, 7, 8, 9 or 10, and n represents 0, 1 or 2, a process for preparing said compound, compositions comprising said compound and its use for combating pests.

  该发明涉及一种化合物，其化学式为（I），其中R代表氢、卤素、烷基、环烷基、烷氧基烷基、烷硫基烷基、卤代烷基、烷氧基、烷硫基，或者代表可选择取代的苯基或苄基，或者代表至少含有一个来自N、O和S的杂原子的可选择取代的杂芳基，m代表3、4、5、6、7、8、9或10，n代表0、1或2，一种制备该化合物的方法，包含该化合物的组合物以及其用于防治害虫的用途。
• [EN] INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION<br/>[FR] INHIBITION DE LA SÉCRÉTION MYCOBACTÉRIENNE DE TYPE VII
  申请人：STICHTING VUMC

  公开号：WO2021040519A1

  公开（公告）日：2021-03-04

  The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a Mycobacterium tuberculosis infection, e.g., in a respiratory system and/or extrapulmonic. The invention further relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds as chemotherapeutic agents. Also, the invention relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds for inhibiting mycobacterial type VII secretion. The compounds have the following formula (Ia), wherein Q and X are, respectively, CH and C, CR2 and C, CH and N, CR2 and N, or N and C; R1 is hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms; R2 is independently selected from hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms, and R3 is optionally substituted linear or branched alkoxy having 1-6 carbon atoms, haloalkyl having 1-6 carbon atoms, n-propyl, 2-propenyl, 2-propynyl, or n-pentyl, or a pharmaceutically acceptable salt of the compound, for use in the prevention or treatment of a bacterial infection.

  该发明涉及化合物及其药用盐，以及它们的医学用途。示例医学用途包括预防和治疗细菌感染，例如分枝杆菌感染，如结核分枝杆菌感染，例如在呼吸系统和/或肺外。该发明还涉及将这些化合物、其药用盐或这些化合物的前体用作化疗药物。此外，该发明涉及将这些化合物、其药用盐或这些化合物的前体用于抑制分枝杆菌的第七型分泌。这些化合物具有以下结构式（Ia），其中Q和X分别是CH和C，CR2和C，CH和N，CR2和N，或N和C；R1是氢、卤素或具有1或2个碳原子的可选择取代的线性或支链烷氧基；R2独立选择自氢、卤素或具有1或2个碳原子的可选择取代的线性或支链烷氧基，R3是可选择取代的具有1-6个碳原子的线性或支链烷氧基、具有1-6个碳原子的卤代烷基、正丙基、2-丙烯基、2-丙炔基或正戊基，或该化合物的药用盐，用于预防或治疗细菌感染。
• 3-PYRIDYL-1,2,4-THIADIAZOLE ALS PESTIZIDE
  申请人：BAYER AG

  公开号：EP0670836A1

  公开（公告）日：1995-09-13
• TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：Yuhan Corporation

  公开号：EP0751943A1

  公开（公告）日：1997-01-08
• INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION
  申请人：Stichting VUmc

  公开号：EP4021898A1

  公开（公告）日：2022-07-06